Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease
- 1 June 2005
- journal article
- clinical trial
- Published by Springer Nature in Journal of Huazhong University of Science and Technology [Medical Sciences]
- Vol. 25 (3) , 348-350
- https://doi.org/10.1007/bf02828164
Abstract
In order to objectively evaluate the efficacy of intravenous gammaglobulin (IVIG) in the prevention and treatment of coronary artery lesion (CAL) in Kawasaki disease (KD) and the related factors influencing the IVIG efficacy, 314 children with KD were reviewed retrospectively and comparatively and were divided into IVIG plus aspirin group and ASA group. The occurrence and restoration of CAL in these two groups as well as many laboratory and clinical indexes including average hospital stay (days), total fever duration, defervescence time, platelet count, erythrocyte sedimentation rate, C reactive protein etc. were observed. The incidence of CAL was 39.5% in the children with KD. In the IVIG+ASA group, the incidence of CAL was 34.3% and 56.0% in ASA group respectively (PP10 days (PP<0.05). IVIG treatment can remarkably shorten the course of patients with KD and decrease the incidence of CAL, but the efficacy of IVIG in the prevention and treatment of KD disease is not as expected by people, therefore, reevaluation of the practical efficacy of IVIG is required.Keywords
This publication has 4 references indexed in Scilit:
- Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future researchArchives of Disease in Childhood, 2002
- The Prevention of Coronary Artery Aneurysm in Kawasaki Disease: A Meta-analysis on the Efficacy of Aspirin and Immunoglobulin TreatmentPediatrics, 1995
- Results of 12 Nationwide Epidemiological Incidence Surveys of Kawasaki Disease in JapanArchives of Pediatrics & Adolescent Medicine, 1995
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASEThe Lancet, 1984